Affiliation:
1. Antiviral Therapeutic Research Unit, Wellcome Research Laboratories, Beckenham, United Kingdom.
Abstract
We have selected a human immunodeficiency virus type 1 (HIV-1) mutant strain with a moderate (sevenfold) level of resistance to the nucleoside analog 2',3'-didehydro-2',3'-dideoxythymidine (D4T or stavudine). After serial passage of the HXB2 strain of HIV-1 in MT4 cells, a novel mutation involving two nucleotide substitutions in codon 75 of the viral reverse transcriptase, altering valine to threonine, was seen. When introduced into a wild-type HIV-1 background by site-directed mutagenesis, the T-75 mutation conferred cross-resistance to the dideoxynucleosides dideoxyinosine and dideoxycytosine as well as to 2',3'-didehydro-2',3'-dideoxycytosine.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference30 articles.
1. Anderson R. C. Wirtz A. Cross M. Adler R. Brunell and L. Dunkle. 1993. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother. abstr. 684. NOTES 1431
2. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'- dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds;Balzarini J.;J. Biol. Chem.,1989
3. Ordered appearance of zidovudine (AZT) resistance mutations during treatment;Boucher C. A. B.;J. Infect. Dis.,1992
4. Brett-Smith H. B. Griffith J. Mellors K. Joiner R. Mark and G. Friedland. 1992. Abstr. VIII Int. Conf. AIDS Amsterdam 1992 abstr. PoB 3011.
5. A molecular clone of HTLV-III with biological activity;Fischer A. G.;Nature (London),1985
Cited by
129 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献